Cationic Sulfonamide and Zwitterionic Lipids for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid nanoparticle systems for nucleic acid delivery face challenges in effectively transporting nucleic acids into cells, necessitating the development of new materials to overcome barriers and address future therapeutic targets.
Innovation Solution
The development of cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids, which can form lipid nanoparticles for efficient delivery of nucleic acids such as siRNA, miRNA, mRNA, CRISPR, tRNA, and sgRNA, by incorporating specific functional groups that enhance cellular uptake and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current lipid nanoparticle systems are used for nucleic acid delivery, then delivery can be achieved, but delivery efficiency and cellular uptake are insufficient
Solution Approach 1:
The patent modifies the chemical structure of lipids by introducing cationic sulfonamide amino groups and zwitterionic amino groups with specific pKa values. These parameter changes in lipid chemistry enable optimized interaction with nucleic acids and cell membranes, thereby improving delivery efficiency and cellular uptake while maintaining nanoparticle formation capability
Solution Approach 2:
The invention creates composite lipid structures combining hydrophobic tails with charged head groups (cationic or zwitterionic). This composite material approach allows the lipid nanoparticle to simultaneously encapsulate nucleic acids through electrostatic interactions and facilitate cellular uptake through enhanced membrane interaction, resolving the contradiction between delivery reliability and productivity
2Adaptability or versatility
If new lipid materials are developed to overcome current limits, then future therapeutic targets can be addressed, but material complexity increases
Solution Approach 1:
The patent designs lipid molecules with universal applicability across multiple therapeutic platforms including siRNA, miRNA, mRNA, and CRISPR delivery. The cationic and zwitterionic amino lipid structures serve multiple functions: nucleic acid complexation, nanoparticle formation, cellular uptake enhancement, and endosomal escape facilitation. This multi-functionality achieves broad therapeutic target coverage without proportionally increasing material complexity
Data Source
AI summary
The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas:wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.